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ABSTRACT
Background
Current animal models of human cardiac disease may be similar in anatomy and 
physiology but are often expensive and tedious to work with. The current need is for a 
model organism that is more efficient to work with in the lab but that still provides an 
accurate model of human cardiac disease. Drosophila melanogaster (D. mel) is such a 
candidate. While 74% of the genes coding for protein are conserved between D. mel and 
human hearts, it is unknown if cardiac medication used in humans, such as atropine and 
propranolol hydrochloride, similarly affect heart rate. I hypothesized that administration 
of atropine and propranolol hydrochloride to third instar larvae would cause an increase 
and decrease respectively in the heart rates of D. mel.
Methods
After larvae hatched and reached the second instar larval phase, they were moved to 
fresh vials. The control group larvae were transferred to vials containing no medication, 
and the experimental group larvae were transferred to vials with 1mM atropine or 
1mM propranolol hydrochloride. The larvae inhabited the new vials for twenty-four 
hours to reach the third instar larvae stage. Larvae were removed, placed individually 
on a microscope slide, and observed using the 4X objective lens of a Leica compound 
microscope. Heart rates of fifty larvae per group were recorded in triplicate over fifteen 
second intervals. 
Results
We observed elevated heart rates of 406 ± 3.18 beats per minute in atropine treated larvae 
when compared to rates of 388 ± 2.07 in control larvae, a 4.83% increase. Moreover, 
heart rates were slowed to an average of 274 ± 2.70 beats per minute in propranolol 
hydrochloride treated hearts, a 29.18% decrease. Both changes in heart rate when 
compared to the control were found to be statistically significant (p<0.001).
Conclusion
Administration of propranolol hydrochloride and atropine increased and decreased the 
heart rates of D. mel respectively. This data supports the hypothesis that D. mel can serve 
as an experimental model for human cardiovascular disease. Future work should build on 
this study and focus on the use of D. mel in preliminary pharmaceutical testing for new 
medication treating cardiovascular conditions.
Keywords: drosophila melanogaster, atropine, propranolol hydrochloride, heart rate 
INTRODUCTION
Models of Cardiovascular Disease
According to the American Heart Association, one American dies of cardiac disease 
every forty seconds (Mozaffarian et al., 2015), and the causation, prevention, and 
treatment of cardiac disease are areas of active research. Organisms of mammalian origin 
are predominantly chosen for studying cardiac disease and include baboons, pigs, sheep, 
dogs, rabbits, rats, and mice (Hasenfuss, 1998). Mammals are typically used due to their 
similarity in physiology, making them candidates to research new treatment methods 
(Patel et al., 2001). Smaller mammals, such as rats and mice, are also useful because 
they can be genetically manipulated and subsequently used to determine the effects of 
mutations in genes relating to cardiac function (Rosenthal and Brown, 2007).  Similarly, 
zebrafish have recently emerged as another model for human cardiac disease research 
and have been used to model congenital heart defects and cardiomyopathies, as well as 
to determine mechanisms that can lead to cardiac disease (Bakkers, 2011). 
These organisms have been pivotal in developing current knowledge regarding the 
physiology of the human cardiovascular system as well as the development and treatment 
of cardiovascular disease. Unfortunately, many of these organisms are inefficient to use 
in the laboratory. Costs to obtain and maintain these organisms in a laboratory setting are 
not trivial. According to the Jackson Laboratory website, purchasing mice for research 
would cost approximately $10.75 per mouse (“Jax mice pricing information,” 2018). 
Genetically modified mice are even more expensive, and, according to the Cyagen 
Biosciences website, could range from $250 to nearly $7,000 depending on the desired 
method of inserting genes into the mouse genome (“Regular transgenic mice,” 2018). 
Rabbits, according to the Charles River website, range from $160 to $330 per rabbit 
depending on weight (“New Zealand white rabbit,” 2018). In addition, many of these 
animals can be difficult to handle and manage within the lab to ensure they are cared for 
humanely throughout research. Mice, for example, can move quickly and may attempt 
to bite the hands of researchers while handling (Buerge and Weiss, 2004). Dogs and 
primates, according to the Johns Hopkins University Animal Care and Use Committee, 
may require tranquilization if they are aggressive and difficult to work with. To advance 
research in this area, it would be advantageous to find an organism that is more efficient 
to utilize in the lab but that still provides an accurate model of human cardiac disease. 
Drosophila melanogaster
D. mel is a candidate for modeling human cardiac disease and is an efficient organism 
to use in the lab for many reasons. One reason is the well documented short lifespan of 
the organism (Linford et al., 2013). D. mel is used as a model of aging due to its short 
life span of approximately fifty days from fertilization of the egg to the death of the 
adult fly. This lifespan is significantly lower than those of typical mammals. A rat, for 
example, has an estimated mean life expectancy of twenty-two months (Baati et al., 
2012). A shorter lifespan allows researchers to study organisms in different stages of 
life over a shorter amount of time. 
Another contributor to the efficiency of using D. mel is the immense research that 
has been done to sequence the genome of the organism (Pandey and Nichols, 2011). 
Scientists know many of the genes in the DNA of D. mel and are thus able to use this 
information to determine whether genes code for disease or for resistance to disease. 
Further, D. mel can incur mutations in genes homologous to genes of human disease 
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naturally or by manipulation (Bier and Bodmer, 2004). This ability allows D. mel to be 
a model for discovering the outcome of mutations in genes necessary for physiological 
function and maintenance of health.
Further benefits include the feasibility of raising the organisms in lab and the inexpensive 
cost (Doke and Dhawale, 2015). D. mel, in contrast to the prices of mammalian models, 
can be purchased for $8.10 per vial containing twenty-five to thirty flies for most 
wildtype and mutant strains. In addition, all of the materials necessary for culturing 
can be purchased for $65.50 (“Carolina easy fly drosophila cultures, living,” 2018).
In addition to being a practical organism to work with, D. mel is a candidate for human 
cardiac disease research. A study performed by Cammarato et al. (2011) determined 
that the proteome, or complete protein makeup, of the D. mel heart contains 498 genes 
vital to heart function. Seventy-four of these genes (15%) were protein products that 
are also produced in humans. Additionally, 73% of the genes were determined to be 
orthologs of genes found in humans and mice. Other experiments researching the 
genetic makeup of the D. mel heart have shown that they are physiologically similar 
to human hearts. The hearts of D. mel can develop structural defects and suffer from 
arrhythmias (irregular heartbeats) or cardiomyopathies (hereditary cardiac disease) 
(Pandey and Nichols, 2011). Another study used D. mel to model the development 
of age-related heart failure (Ocorr, Akasaka, and Bodmer, 2007). Due to genetic 
similarity, D. mel hearts develop heart failure caused by errors in pacing as well as 
arrhythmias, key factors in researching age-related heart failure. This research suggests 
that D. mel has a promising future in determining genetic contributions to cardiac 
disease. Anatomically, however, the heart of D. mel is different from that of a human 
(Figure 1). 
Figure 1: D. mel cardiac 
tube captured during the 
recording of heart rate.
The image was taken of a 
D. mel larvae under the 4X 
objective lens of a Leica 
compound microscope. The 
outline of the head of the 
cardiac tube can be observed. 
Surrounding the cardiac 
tube is a single layer of 
cardiomyocytes.
In a study identifying the genetic components of heart development and function, it 
was noted that the D. mel heart has only one chamber, referred to as the cardiac tube, 
and lacks coronary arteries (Seyres, Röder, and Perrin, 2012). This structure is different 
than that of a human heart, in which there are four highly vascularized chambers. 
Another study notes that the D. mel heart has only one layer of cardiomyocytes (heart 
cells) whereas the human heart has two sections of cardiomyocytes, the myocardium 
and endocardium (Medioni et al., 2009). Despite the anatomical differences though, 
the similarity in genetics and proteome present a convincing case for D. mel as a model 
of human cardiovascular disease.
Despite current advances in understanding genomic similarities between D. mel 
and other organisms typically used as models, it is still not known whether the D. 
mel cardiovascular system is capable of responding similarly to heart medication. 
Understanding physiological responses of the D. mel heart to heart medication could 
further qualify it as a model of human cardiovascular disease and open new doors of 
research. 
Atropine
Atropine is frequently prescribed to increase heart rate in instances of hypotension 
(“Atropine,” 2014). The drug is administered to those suffering from bradycardia, a 
condition of extremely low heart rate to increase firing of the SA node in the heart (Al, 
2014).
Atropine increases heart rate in humans by preventing acetylcholine from binding to 
sinoatrial and atrioventricular nodes. It does this by blocking muscarinic acetylcholine 
receptors (mAchRs) and, as a result, contraction of these pacemaking nodes increases 
(Kinkade, 2012). For this drug to effect D. mel in a similar fashion, the organism must 
have conserved receptors with the same capability of being blocked by atropine. One 
study determined which G-protein receptors in D. mel were coupled to mAchRs, the 
active site of atropine (Ren, Folke, Hauser, Li, and Grimmelikhuijzen, 2015). They 
found that mammals have five mAchRs and that D. mel has only two, an A-type and 
B-type. Specifically, the A-type mAchRs in D. mel were determined to have a similar 
structure to the mammalian receptors. For these receptors to function similarly to human 
mAchRs, the D. mel heart would need to be similarly innervated. It was originally 
thought that the D. mel heart was not innervated. It was discovered, however, that the 
D. mel heart is indeed innervated (Dulcis and Levine, 2003). At the larval stage, heart 
rate is controlled by a pacemaker structure thought to be located in the caudal region 
of the heart. With all of this in mind, it is still not known whether these receptors 
can invoke the same response on the innervating structure of the D. mel heart. If the 
mAchRs of D. mel can respond to atropine similarly to humans, this would support our 
knowledge of D. mel as a model for human cardiac disease and medicinal research.
Propranolol hydrochloride
While the effect of atropine increases heart rate, propranolol hydrochloride is a 
β-blocker that decreases heart rate and is prescribed by physicians for patients suffering 
The Effects of Heart Medication on the Heart Rates of Drosophila Melanogaster Felicia A. Baer
3
Baer: The Effects of Heart Medication on the Heart Rates of Drosophila
Published by Digital Commons @ Olivet, 2018
10 11
from heart failure (Coppola, Froio, and Chiumello, 2015). Results of one study suggest 
that β-blockers benefit patients by reducing heart rate and thereby inducing relaxation 
which may have an effect on diastolic filling of the heart (Dobre et al., 2007). 
β-blockers reduce heart rate by blocking beta1-adrenergic receptors (βARs), reducing 
sinoatrial node automaticity and therefore heart rate (Gibson and Raphael, 2014). A 
study measuring the effects of βARs agonists versus antagonists on D. mel showed that 
antagonist β-blockers, such as propranolol hydrochloride, decreased mortality by 6.4% 
(Spindler et al., 2013). The same study also showed that D. mel does not have βARs but 
possesses a family of G-protein receptors that are structurally and functionally related 
to βARs. However, it is not known whether treatment with propranolol produces an 
effect on heart rate. If the βAR-like receptors in D. mel can respond to propranolol 
hydrochloride in a similar way to humans, this would further support D. mel as a model 
for human cardiac disease and medicinal research.
The Effects of Heart Medication on D. mel
While there is proteomic support for a conserved mechanism of regulation, it is unknown 
if heart medications such as atropine and propranolol hydrochloride have a similar 
effect on heart rate. We hypothesized that atropine and propranolol hydrochloride in the 
growth media of third instar larvae would cause an increase and decrease respectively 
in the heart rates of D. mel. Characterization of the pharmacologic activity of these 
two drugs on D. mel cardiac activity would further clarify if there are conserved 
mechanisms of heart rate regulation between the invertebrate D. mel and mammals 
and would lend further support to using D. mel as a model for human cardiac disease. 
METHODS
Materials and D. mel Culturing
Wild type D. mel were purchased from Carolina Biological and atropine and propranolol 
hydrochloride were purchased from Sigma Aldrich. To maintain a constant living 
environment, the flies were kept at 22°C and transferred to new vials to mate. The 
vials were made by mixing equal amounts of Instant Drosophila Medium purchased 
from Carolina Biological with sterile deionized water in drosophila culturing vials with 
sponge plugs. The flies were given several days to lay eggs, and once larvae were seen 
in the vials the adults were moved to new vials to repeat the process and obtain stock 
vials of adult flies.
Treatment with Atropine and Propranolol Hydrochloride
The experimental procedure required a time span of seven days to complete (Figure 2) 
and was completed three times in succession. On the first day, adult flies from stock vials 
were placed in three new vials to mate. Over the following four to five days, the adult 
flies laid eggs in the medium that hatched into larvae and began to mature. By the sixth 
day, the larvae reached the second instar larval phase. Larvae at this stage were preferred 
due to their burrowing nature in which they tunnel deep into their growth media, thereby 
increasing exposure to medication in the media. Second instar larvae were transferred to 
Figure 2: Timeline of procedure detailing when flies were moved to new vials and when heart rates were 
recorded. On Day 1, adult flies were moved to new vials to mate. Over the next few days, the flies were left to lay 
eggs. Once the larvae hatched from the eggs and entered the second instar larval stage of development, they were 
moved to fresh media. At this stage, atropine or propranolol hydrochloride were administered to the media. After 
twenty-four hours, the third instar larval heart rates were recorded.
fresh vials that contained the experimental treatment. For the control group, fifty second 
instar larvae were moved to vials containing media made with sterile deionized water. 
For the first experimental group, fifty second instar larvae were transferred to vials with 
1mM propranolol hydrochloride in the media. For the second experimental group, fifty 
second instar larvae were transferred to vials with 1mM atropine in the media. 1mM 
concentrations of each medication were utilized after performing a preliminary test of 
a tenfold range of molar concentrations, of which 1mM concentrations were found to 
display an effect on heart rate without mortality of the larvae. The second instar larvae 
inhabited the new vials for twenty-four hours, maturing into third instar larvae during this 
time at which point heart rates were observed.
Heart Rate Assessment of Third Instar Larvae
The heart rate of each third instar larvae of the control and treatment groups was observed 
three times in fifteen second intervals. Larvae were removed, placed individually on 
a microscope slide, and observed using the 4X objective lens of a Leica compound 
microscope. Beating hearts were visualized through the transparent skin of the dorsal 
side when larvae were placed on their ventral side. Once the microscope was properly 
focused on the larva, a fifteen second timer with a ten second interval of rest was 
started. A tap counter was used to count the number of times the heart beat during each 
fifteen second interval. After a ten second rest, the process was repeated until a total of 
three heart rates had been recorded for the larva.
Values were averaged for each larva, with the resulting fifty averages used to calculate 
the average heart rate and standard error for the group. To determine the significance 
of the two experimental groups from the control group, a T-Test was performed. The 
statistical analysis was done using Microsoft Excel.
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RESULTS
Second instar D. mel larvae were treated with 1mM atropine or 1mM propranolol 
hydrochloride for twenty-four hours, after which the heart rates of fifty larvae were 
assessed at the third instar larval stage for each treatment. These averages were compared 
to that of untreated control larvae (Figure 3). Atropine treatment resulted in a heart rate 
of 406 ± 3.18 beats per minute, which represented a 4.83% increase in heart rate over 
control hearts (388 ± 2.07 bpm). On the contrary, propranolol hydrochloride treated 
larvae had hearts rates of 275 ± 2.70 beats per minute, which was a 29.18% decrease 
in heart rate when compared to controls. Both changes in heart rate were statistically 
significant (p<0.001). These results indicate that both heart rate medications influenced 
a change in the heart rates of D. mel larvae.
  
DISCUSSION
This research aimed to test whether D. mel larvae can respond similarly to humans when 
treated with heart medication. We observed a significant difference in the heart rates 
of the larvae that were treated with propranolol hydrochloride. Control larvae had an 
average heart rate of 388 ± 2.07 beats per minute while the propranolol hydrochloride 
treated larvae had an average heart rate of 275 ± 2.70 beats per minute (p<0.001).  This 
supports the hypothesis that propranolol hydrochloride decreases the heart rate of third 
instar larvae and demonstrates that D. mel responds to heart medication similarly as 
humans. Further, we also observed a difference in the heart rates of the larvae treated 
with atropine. Larvae treated with atropine had an increased heart rate of 406 ± 3.18 
beats per minute (p<0.001). This supports the hypothesis that atropine increases the 
heart rate of third instar larvae and demonstrates that D. mel can respond to heart 
medication similarly as humans.
The effects of the two medications on the heart rates of D. mel support previous work 
that demonstrated the conserved mAchRs and βARs in D. mel. One study determined 
the protein content of the two mAchRs found in the D. mel genome (Ren et al., 2015). 
They concluded that one of the two mAchRs is pharmacologically similar to that of 
humans; however, they did not demonstrate that D. mel was capable of responding 
to atropine in a similar way to humans. The increase in heart rate due to atropine 
supports this research, further supporting the notion that the mAchRs in D. mel are 
pharmacologically similar to human mAchRs. Another study used propranolol 
hydrochloride to study the effects of β-blockers on the lifespan of D. mel (Spindler 
et al., 2013). In this research, it is explained that D. mel do not have the same βARs 
as humans but rather utilize a family of G-protein receptors that may function very 
similarly to that of humans. The decrease in heart rate due to propranolol hydrochloride 
that was observed in this study would support this research and suggest that the heart 
of D. mel has conserved receptors capable of responding to the β-blocker propranolol 
hydrochloride in a similar manner to humans.
To evaluate the similarity between the effects of atropine and propranolol on the 
heart rates of D. mel larvae and humans, it is necessary to compare the results of 
this experiment to those found by other studies. After the administration of atropine, 
there was an observed 4.83% increase in larval heart rate. One study, which measured 
heart rate after the endobronchial administration of atropine in humans, found a 16% 
increase in heart rate at a dosage of 0.02 mg/kg (Paret et al., 1999). The difference 
between this 16% increase in heart rate from the observed 4.83% increase in heart 
rate is due to differences in atropine dose as well as the method of delivering the 
medication.  Another study found that atropine increased heart rate in humans by 
13.1 beats per minute (bpm) after 80 minutes at a dosage of 0.15 µg/kg/min (Bruck, 
Ulrich, Gerlach, Radke, and Brodde, 2003). The difference between the 13.1 bpm 
increase from the approximately 18 bmp increase observed in this experiment is due to 
differences in dose.  There was also an observed 29.18% increase in larval heart rate 
after the administration of propranolol hydrochloride. In one study, participants who 
received 40mg of propranolol hydrochloride were found to have resting heart rates of 
62 bpm after five hours as opposed to 72 bpm in participants who received the placebo 
(Joannides et al., 2006). The difference in recorded decrease in heart rate is due to the 
difference in dose administered and time between doses. Larvae in this experiment 
were exposed to propranolol hydrochloride for twenty-four hours before heart rate was 
recorded; however, participants in the study described above were exposed to the drug 
for only five hours. This difference in time could influence the observed decrease in 
heart rate in the two experiments. Through comparing the results of this experiment 
to those of other studies, it is apparent that the effects of the drugs on the heart rates 
of D. mel larvae are similar. To confirm this conclusion, future studies need to employ 
concentrations of the drugs that more closely parallel those used in human studies.
There were limitations in the study design that should be recognized and improved 
upon in future research.  Most importantly, the research should have been completed 
as a blinded study. This would allow for experimental recording of heart rates while 
Figure 3: Atropine and 
Propranolol Hydrochloride 
act as respective positive 
and negative chrontropes 
of D. mel heart rates. 
Average heart rates of treated 
third instar larvae in the 
control, atropine (1mM), and 
propranolol hydrochloride 
(1mM) groups were assessed 
by observing the heart rate 
using the 4X objective 
lens of a Leica compound 
microscope. Heart rates 
were recorded in triplicate 
for fifty in each group. Data 
are presented as mean plus 
and minus the standard error. 
Respective increase and 
decreases of heart rate due 
to atropine and propranolol 
hydrochloride treatments 
were statistically significant 
(p<0.001). 
The Effects of Heart Medication on the Heart Rates of Drosophila Melanogaster Felicia A. Baer
5
Baer: The Effects of Heart Medication on the Heart Rates of Drosophila
Published by Digital Commons @ Olivet, 2018
14 15
unaware of the group being observed. Performing the experiment in this way would 
eliminate the possibility of bias. Further, there are more precise methods of recording 
heart rate that could have been used. At heart rates as rapid as that of D. mel, human 
error in manually counting is inevitable. With additional funding, software could be 
purchased which would allow for computer-generated analysis of videos of the beating 
larval heart that would more accurately assess the heart rate (Vogler and Ocorr, 2009).
While further research will add to our knowledge in this area, the data collected in 
this experiment suggest that the D. mel heart responds to atropine and propranolol 
hydrochloride as the human heart does. If this is indeed the case, future research could 
be performed to discover whether D. mel has the capability of responding to other 
heart medications. In the future, D. mel could be used as a model organism for research 
being performed on the effects of these heart medications. 
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